RTW.LSE RTW Venture Fund Ltd
- Market cap
- USD 751M
- P/E
- 1.8x
- P/B
- 0.76x
- ROE
- 73.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is RTW.LSE undervalued?
Graham numberThe Graham number of RTW Venture Fund Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RTW Venture Fund Ltd fundamental analysis
No fundamental analysis for RTW Venture Fund Ltd yet.
RTW Venture Fund Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RTW Venture Fund Ltd
RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
Full company profileRTW Venture Fund Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RTW Venture Fund Ltd annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 28.0M | 39.7M | 163M | -60.9M | -36.5M | 87.9M | 43.5M | 258M | 230M |
| Gross Profit | 28.0M | 39.7M | 163M | -60.9M | -36.5M | 67.0M | 38.7M | 251M | 208M |
| Operating Income | 27.9M | 38.7M | 161M | -64.3M | -38.7M | -2.99M | 38.9M | 245M | 694M |
| EBITDA | 27.9M | 38.7M | 161M | -64.3M | -38.7M | 87.5M | 42.9M | 245M | 694M |
| Net Income | 27.9M | 38.7M | 161M | -64.3M | -39.4M | 83.2M | 34.2M | 245M | 677M |
| EPS | 0.17 | 0.27 | 0.67 | -0.27 | -0.17 | 0.40 | 0.11 | 0.63 | 2.10 |
| Balance Sheet | |||||||||
| Total Assets | 65.8M | 216M | 421M | 439M | 402M | 446M | 760M | 1.07B | 1.31B |
| Total Liabilities | 32.2K | 1.41M | 8.29M | 52.0M | 53.6M | 17.2M | 127M | 204M | 300M |
| Shareholders' Equity | 65.7M | 214M | 413M | 387M | 326M | 399M | 607M | 801M | 922M |
| Cash & Short-term Investments | 31.3K | 10.7M | 4.55M | 6.48M | 6.97M | 2.72M | 5.36M | 5.99M | 3.65M |
| Total Debt | - | 203K | 6.67M | - | 12.4M | 1.20M | 95.2M | 161M | 210M |
| Cash Flow | |||||||||
| Operating Cash Flow | -44.3K | -66.2M | -10.8M | -44.9M | -15.7M | 33.5M | -124M | 54.2M | 175M |
| Capital Expenditure | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 37.3M | 38.5M | 5.00 | 0.00 |
| Free Cash Flow | -44.3K | -66.2M | -57.1M | -44.9M | 10.4M | 70.9M | -124M | 54.2M | 175M |
| Ratios | |||||||||
| ROE | 42.5% | 18.1% | 38.9% | -16.6% | -12.1% | 20.8% | 5.6% | 30.6% | 73.4% |
| ROA | 42.5% | 17.9% | 38.2% | -14.6% | -9.8% | 18.6% | 4.5% | 22.9% | 51.6% |
| Net Profit Margin | 99.7% | 97.5% | 98.7% | - | - | 94.7% | 78.6% | 95.0% | 294.5% |
| Debt to Equity | - | 0.00x | 0.02x | - | 0.04x | 0.00x | 0.16x | 0.20x | 0.23x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
RTW Venture Fund Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 4.97M | 0.02 | - |
| 2020 | USD 4.15M | 0.02 | 2.6% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns RTW Venture Fund Ltd
- Insiders 16.34%
- Institutions 14.59%
- Public & others 69.07%
- Shares outstanding 320M
RTW Venture Fund Ltd company profile
- Company name
- RTW Venture Fund Ltd
- Ticker
- RTW.LSE
- ISIN
- GG00BKTRRM22
- Exchange
- London Exchange
- Sector
- Financial Services
- Industry
- Commercial Services & Supplies
- Fiscal year end
- December
- Address
- 40 10th Avenue, New York, NY, United States, 10014
- Phone
- 646 597 6980
About RTW Venture Fund Ltd
RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. The fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
RTW Venture Fund Ltd management
4- Baroness Nicola BlackwoodSenior Independent Non-Executive Director · born 1979
- Ms. Krisha McCuneDirector of Investor Relations
- Dr. Roderick Tze Ian Wong M.B.A., M.D.Investment Professional · born 1977
- Mr. Woody StilemanInvestment Professional